ERBB2 and breast carcinoma: On December 20, 2019, the FDA granted accelerated approval to T-DXd to metastatic HER2-positive breast cancer based on its extraordinary efficacy results and manageable safety profiles from the DESTINY-Breast01 clinical trial (NCT03248492)[75].